Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Ascendis Pharma A S Receives Orphan Designation For Transcon Pth For Treatment Of Hypoparathyroidism In Europe is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease –– ATH434-201 Phase 2 Baseline Data Confirm ... Read More
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin
By Chris Wack Cadrenal Therapeutics said that the U.S. Food and Drug Administration has granted tecarfarin orphan drug designation for the prevention ... Read More
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech. Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus